Page 216 - 20211214_OHKF_Health_Finance_Research_Report_E (1)
P. 216

3.   To build and sustain partnerships with key players in the health system, the purchaser
                 should promote cross-departmental and multi-sectoral collaboration
                 beyond public and private sectors in health programmes (Chu et al.,
                 2019). Specifically, the design of the Scheme should address intricate stakeholder
                 dynamics between key actors that include the Government, development partners,
                 providers (capacity and willingness to engage) and users (preferences, beliefs,
                 awareness) (Nachtnebel et al., 2015; Wong et al., 2015).

                 a.   The Government and the purchaser should engage with industry
                     stakeholders, such as from the pharmaceutical industry and
                     insurance industry, to garner perspectives of how to improve population
                     health and meet the growing health demand, as showcased in Chapter 4.1.
                     Consideration should be given to the current practices of both industries, as
                     insurance companies have begun incorporating prevalent chronic disease
                     management into insurance products. Additionally, pharmaceutical companies
                     have different guidelines and prices when supplying drugs to doctors in private
                     sector, which has created challenges for increasing the uptake of PPP
                     programmes by private service providers. Thus, exchanging experiences with and
                     gaining insights from commercial entities will broaden the Government’s
                     perspective on how to incentivise private sector usage among the public and the
                     participation of private service providers in the Scheme.

                 b.   The Government should consult with private sector providers to ensure that they
                     are offered a role in defining the benefit package, payment mechanisms, and
                     actively engage them in provider reforms that potentially promote the achievement
                     of high service quality.

                 c.   To increase purchaser and provider transparency, and also allowing patients to
                     make informed decisions on their choice of medication purchase, the
                     Government and the purchaser should work with the private
                     sector to publicise and disseminate the costs of drugs available
                     in both the public and private sectors.








































       214
   211   212   213   214   215   216   217   218   219   220   221